Company:  LUCID DIAGNOSTICS INC. (LUCD)
Form Type:  3
Filing Date:  10/13/2021 
CIK:  0001799011 
Address:  ONE GRAND CENTRAL PLACE
SUITE 4600
 
City, State, Zip:  NEW YORK, New York 10165 
Telephone:  212-949-4319 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$9.35  
Change: 
-2.41 (-20.49%)  
Trade Time: 
Oct 15  
Market Cap: 
$345.88M
Trade LUCD now with 

© 2021  
Description of Business
We are a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). We believe that our lead products, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell Collection Device in a brief noninvasive office procedure, constitute the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent EAC deaths, through early detection of esophageal precancer and cancer in at-risk GERD patients. We believe EsoGuard could have as great an impact in preventing EAC deaths as widespread Pap test screening has had in preventing cervical cancer deaths.
Register and access this filing in:     
  FORM 3
    NAME AND TITLE
    NON DERIVATIVE SECURITIES
    DERIVATIVE SECURITIES
    REPORTING OWNERS
    SIGNATURES